The delivery challenge is posed by the blood–brain barrier (BBB), which prevents around 95% of small molecules, and almost all therapeutic biologics, from leaving the bloodstream and entering ...

The blood–brain barrier (BBB) is meant to protect the brain from noxious agents; however, it also significantly hinders the delivery of therapeutics to the brain. Several strategies have been ...

More information: Wang, C., et al. Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system, Nature Biotechnology (2024).

Alzheimer’s is the most common form of dementia — it causes memory loss, confusion, thinking problems and behavioral changes.

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that ...

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- ...